你的原文应该来自这里网页链接。
一般来说,只有技术路线根本变化的才称之为“代”。技术路线相同而只是疫苗成分改变,不能称之为下一代疫苗。
是否对新的变异株针对性研制新的疫苗,是要根据突变位点、新突变株的毒性传播能力以及演变趋势、疫苗设计、尤其是临床数据等来综合判断的,并非是出现出现突变就马上研制新疫苗。换句话说,突变株特异性疫苗的效力未见得比原始株疫苗的高,甚至可能会低。
这是原文:
"In terms of practical considerations, at the recent meeting of the VRBPAC, there was relatively uniform agreement that a single vaccine composition used by all manufacturers was desirable and that data would be needed to inform and drive the selection of a monovalent, bivalent, or multivalent COVID-19 vaccine," Marks, Woodcock and Califf wrote. "There was also general agreement that, should a new vaccine composition be recommended based on the totality of the available clinical and epidemiologic evidence, optimally it could be used for both primary vaccination as well as booster administration."
我很希望国内尽快打上高效的mRNA疫苗。